Literature DB >> 3278555

Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.

E Tolosa1, M J Martí.   

Abstract

Meige's syndrome is a form of cranial dystonia characterized by the presence of bilateral dystonic spasms of the facial muscles and frequently of other cranial muscles as well. Its most common and disabling manifestation is blepharospasm which can render the patient functionally blind. Several types of orbicularis oculi spasms occur in Meige's syndrome: brief clonic spasms, prolonged dystonic spasms, constant tonic contraction, and "apraxia" of lid opening. In the completed form of the syndrome, blepharospasm is typically associated with lower facial or oromandibular dystonia. Spasms of the neck and limb muscles, generally mild, and action tremor not uncommonly accompany the cranial dystonia. In most patients the cause of the spasms is unknown. This so-called idiopathic or primary form of Meige's syndrome is considered an adult form of adult onset dystonia. Secondary Meige's syndrome can be encountered in the context of several neurodegenerative disorders, chronic administration of neuroleptics, levodopa, or other drugs, and in patients with focal brain lesions. These secondary cases of Meige's syndrome suggest that a dysfunction of the basal ganglia or of the mesencephalic/diencephalic region plays an important role in the pathophysiology of this dystonic syndrome. Recent neurophysiologic studies and postmortem findings in some patients also support the notion that disease of the brain stem contributes to the pathophysiology of orofacial dystonia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278555

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  21 in total

1.  Meige's syndrome in dementia with Lewy bodies.

Authors:  Naji Tabet; Saraswathy Sivaloganathan
Journal:  J R Soc Med       Date:  2002-04       Impact factor: 5.344

2.  Dry eye and Meige's syndrome.

Authors:  K Tsubota; T Fujihara; M Kaido; A Mori; M Mimura; M Kato
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  Descending brainstem projections of the pedunculopontine tegmental nucleus in the rat.

Authors:  I Grofova; S Keane
Journal:  Anat Embryol (Berl)       Date:  1991

4.  Tardive and idiopathic oromandibular dystonia: a clinical comparison.

Authors:  E K Tan; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

5.  Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm.

Authors:  Francisco Vivancos-Matellano; Ana Rodríguez-Sanz; Yolanda Herrero-Infante; Javier Mascías-Cadavid
Journal:  Neuroophthalmology       Date:  2018-11-26

6.  Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms.

Authors:  Natlada Limotai; Criscely Go; Genko Oyama; Nelson Hwynn; Theresa Zesiewicz; Kelly Foote; Roongroj Bhidayasiri; Irene Malaty; Pam Zeilman; Ramon Rodriguez; Michael S Okun
Journal:  J Neurol       Date:  2011-05-07       Impact factor: 4.849

7.  Palatal myoclonus associated with orofacial buccal dystonia.

Authors:  Shi-Nae Park; Kyoung Ho Park; Do Hyun Kim; Sang Won Yeo
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-02-07       Impact factor: 3.372

8.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

Review 9.  The focal dystonias: current views and challenges for future research.

Authors:  H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

10.  Chronic acquired hepatocerebral degeneration presenting with Meige's syndrome and behavioral symptoms fully reversed by liver transplantation.

Authors:  Andrea Stracciari; Luca Spinardi; Maria Guarino
Journal:  Neurol Sci       Date:  2021-07-19       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.